

Fabrice Carrat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6545654/publications.pdf>

Version: 2024-02-01

320
papers

19,240
citations

13827

67
h-index

15218

126
g-index

344
all docs

344
docs citations

344
times ranked

20051
citing authors

#	ARTICLE	IF	CITATIONS
1	Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). <i>Liver International</i> , 2022, 42, 38-49.	1.9	5
2	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 677-689.	1.5	6
3	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100390.	2.6	15
4	Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. <i>JAMA Internal Medicine</i> , 2022, 182, 19.	2.6	183
5	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). <i>Liver International</i> , 2022, 42, 249-252.	1.9	3
6	Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France. <i>Infection</i> , 2022, 50, 257-262.	2.3	10
7	Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2022, 13, 100278.	3.0	109
8	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2022, 22, 94.	1.3	6
9	Estimating the burden of influenza-related and associated hospitalizations and deaths in France: An eight-season data study, 2010-2018. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 717-725.	1.5	9
10	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. <i>Hepatology</i> , 2022, 76, 139-154.	3.6	42
11	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). <i>Clinical Nutrition</i> , 2022, 41, 610-619.	2.3	8
12	Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.2	3
13	Comparing SF-36 Scores Collected Through Web-Based Questionnaire Self-completions and Telephone Interviews: An Ancillary Study of the SENTIPAT Multicenter Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e29009.	2.1	8
14	Emotional and attention-deficit/hyperactivity disorder symptoms of preterm vs. full-term children during COVID-19 pandemic restrictions. <i>Pediatric Research</i> , 2022, 92, 1749-1756.	1.1	6
15	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. <i>JHEP Reports</i> , 2022, 4, 100481.	2.6	3
16	Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). <i>Journal of Infection</i> , 2022, 84, e101-e104.	1.7	15
17	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
18	Persistent symptoms after the first wave of COVID-19 in relation to SARS-CoV-2 serology and experience of acute symptoms: A nested survey in a population-based cohort. <i>Lancet Regional Health - Europe</i> , The, 2022, 17, 100363.	3.0	12

#	ARTICLE	IF	CITATIONS
19	Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France. <i>Viruses</i> , 2022, 14, 957.	1.5	5
20	Multilabel classification of medical concepts for patient clinical profile identification. <i>Artificial Intelligence in Medicine</i> , 2022, 128, 102311.	3.8	10
21	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617.		2
22	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
23	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	1.8	33
24	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. <i>Journal of Cannabis Research</i> , 2022, 4, .	1.5	1
25	Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. <i>Journal of Infection</i> , 2022, 85, e104-e108.	1.7	29
26	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101459.	0.7	4
27	Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. <i>Journal of Hepatology</i> , 2021, 74, 37-47.	1.8	21
28	Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France. <i>Liver International</i> , 2021, 41, 2328-2340.	1.9	3
29	Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 169.	1.3	33
30	Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based "CONSTANCES" cohort. <i>European Journal of Epidemiology</i> , 2021, 36, 219-222.	2.5	54
31	When lockdown policies amplify social inequalities in COVID-19 infections: evidence from a cross-sectional population-based survey in France. <i>BMC Public Health</i> , 2021, 21, 705.	1.2	44
32	Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER). <i>Liver International</i> , 2021, 41, 1694-1698.	1.9	0
33	Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. <i>Infectious Diseases Now</i> , 2021, 51, 380-382.	0.7	28
34	Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. <i>Lancet Public Health</i> , The, 2021, 6, e408-e415.	4.7	54
35	Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. <i>International Journal of Epidemiology</i> , 2021, 50, 1458-1472.	0.9	75
36	Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SerPRIM Study Protocol. <i>Pathogens</i> , 2021, 10, 911.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Seasonal burden of severe influenza virus infection in the critically ill patients, using the Assistance Publique-HÃpitalaux de Paris clinical data warehouse: a pilot study. <i>Annals of Intensive Care</i> , 2021, 11, 117.	2.2	3
38	Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1498-1511.	2.3	59
39	Body weight, body composition and the risk of SARS-CoV-2 infection in a large population-based sample. <i>Journal of Internal Medicine</i> , 2021, 290, 1268-1271.	2.7	1
40	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	2.6	6
41	Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study. <i>Lancet Regional Health - Europe</i> , The, 2021, 7, 100148.	3.0	57
42	Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. <i>HIV Medicine</i> , 2021, 22, 924-935.	1.0	2
43	Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2021, 75, 565-571.	1.8	53
44	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101713.	0.7	10
45	Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. <i>Journal of Clinical Virology</i> , 2021, 144, 104987.	1.6	2
46	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100171.	3.0	70
47	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1138-1146.	1.9	37
48	Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1050-1050.	1.9	1
49	Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-SantÃ cohort. <i>BMC Medicine</i> , 2021, 19, 290.	2.3	26
50	Children's mental and behavioral health, schooling, and socioeconomic characteristics during school closure in France due to COVID-19: the SAPRIS project. <i>Scientific Reports</i> , 2021, 11, 22373.	1.6	15
51	Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir new clues from Europe. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 659-659.	1.9	0
52	Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. <i>Gut</i> , 2020, 69, 852-858.	6.1	46
53	Comparing interferon-free with interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox. <i>Journal of Viral Hepatitis</i> , 2020, 27, 329-332.	1.0	1
54	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , 2020, 19, 102446.	2.5	13

#	ARTICLE	IF	CITATIONS
55	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 879-884.	1.6	21
56	Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C infected patients (ANRS Tj ETQq0 0 0 rgBT /Overlock 10	1.0	13
57	Predictive models for hepatocellular carcinoma (HCC) occurrence in patients with chronic hepatitis C and sustained virological response (SVR) achieved with direct acting anti-viral (DAA) included in the ANRS CO22 hepather cohort. <i>Journal of Hepatology</i> , 2020, 73, S106.	1.8	2
58	Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study). <i>Journal of Hepatology</i> , 2020, 73, S797-S798.	1.8	2
59	Sofosbuvir+Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020, 27, 964-973.	1.0	5
60	Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	1.8	52
61	Non-influenza respiratory viruses in adult patients admitted with influenza-like illness: a 3-year prospective multicenter study. <i>Infection</i> , 2020, 48, 489-495.	2.3	23
62	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	1.8	47
63	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	1.9	66
64	Biased and unbiased estimation of the average length of stay in intensive care units in the Covid-19 pandemic. <i>Annals of Intensive Care</i> , 2020, 10, 135.	2.2	25
65	Acute and Chronic Sarcoid Arthropathies: Characteristics and Treatments From a Retrospective Nationwide French Study. <i>Frontiers in Medicine</i> , 2020, 7, 565420.	1.2	5
66	The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1489-1492.	1.0	13
67	Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1276-1283.	1.0	1
68	SAT-490-No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort. <i>Journal of Hepatology</i> , 2019, 70, e849-e850.	1.8	0
69	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response. <i>Journal of Hepatology</i> , 2019, 71, 446.	1.8	2
70	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019, 70, e2-e3.	1.8	11
71	Direct-acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic?. <i>Liver International</i> , 2019, 39, 446-447.	1.9	0
72	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 300.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Ischemic stroke in giant-cell arteritis: French retrospective study. <i>Journal of Autoimmunity</i> , 2019, 99, 48-51.	3.0	38
74	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019, 393, 1453-1464.	6.3	449
75	Inflammatory disorders associated with trisomy 8 myelodysplastic syndromes: French retrospective case-control study. <i>European Journal of Haematology</i> , 2019, 102, 63-69.	1.1	20
76	Gastrointestinal Behçet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1782-1788.	0.6	22
77	Obstetrical morbidity related to anti-SSA antibodies: Data from a French monocentric retrospective study. <i>Joint Bone Spine</i> , 2019, 86, 523-524.	0.8	0
78	Letter: more studies are needed to elucidate the impact of HBV/HCV coinfection on cirrhosis and its consequences? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 543-544.	1.9	0
79	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. <i>American Journal of Hematology</i> , 2018, 93, E114-E117.	2.0	94
80	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 892-899.e2.	2.4	80
81	Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. <i>Gut</i> , 2018, 67, 1261-1268.	6.1	104
82	Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?. <i>Clinical Infectious Diseases</i> , 2018, 66, 317-318.	2.9	4
83	Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1399-1405.	0.6	21
84	Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 337-346.e10.	0.6	411
85	Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 797-805.	0.9	3
86	Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 177-188.	3.7	79
87	Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. <i>RMD Open</i> , 2017, 3, e000344.	1.8	24
88	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 730-734.	2.5	63
89	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUIPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017, 10, 605-614.	1.1	4
90	Immunity against influenza A(H1N1) infections is determined by age at the time of initial strain circulation. <i>Epidemiology and Infection</i> , 2017, 145, 141-147.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 261-276.	1.0	12
92	Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. <i>Clinical Microbiology and Infection</i> , 2017, 23, 253-259.	2.8	60
93	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 533-541.	1.9	35
94	The negative impact of <scp>HBV</scp>/<scp>HCV</scp> coinfection on cirrhosis and its consequences. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1054-1060.	1.9	66
95	Effect of resistance-associated substitutions on retreatment of direct acting antiviral-exposed patients in the real-world setting (ANRS CO22 HEPATHER). <i>Journal of Hepatology</i> , 2017, 66, S84.	1.8	3
96	Immune activation, smoking, and vaccine response. <i>Aids</i> , 2017, 31, 171-173.	1.0	12
97	Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1679.	3.8	424
98	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. <i>Autoimmunity Reviews</i> , 2017, 16, 903-910.	2.5	32
99	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , 2017, 130, 1377-1380.	0.6	146
100	Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. <i>Hepatology</i> , 2017, 65, 152-163.	3.6	93
101	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	1.8	100
102	Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement. <i>PLoS ONE</i> , 2017, 12, e0163586.	1.1	49
103	Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. <i>BMC Medical Research Methodology</i> , 2017, 17, 160.	1.4	9
104	Comparing Inpatient Satisfaction Collected via a Web-Based Questionnaire Self-Completion and Through a Telephone Interview: An Ancillary Study of the SENTIPAT Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e293.	2.1	8
105	Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons. <i>World Journal of Gastroenterology</i> , 2017, 23, 7037-7046.	1.4	6
106	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. <i>PLoS ONE</i> , 2016, 11, e0157191.	1.1	19
107	Applications of Extreme Value Theory in Public Health. <i>PLoS ONE</i> , 2016, 11, e0159312.	1.1	40
108	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 252-261.	1.9	111

#	ARTICLE	IF	CITATIONS
109	A systematic review on the effect of the organisation of hospital discharge on patient health outcomes. <i>BMJ Open</i> , 2016, 6, e012287.	0.8	17
110	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	0.6	149
111	Heterogeneous shedding of influenza by human subjects and its implications for epidemiology and control. <i>Scientific Reports</i> , 2016, 6, 38749.	1.6	16
112	Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1. <i>JAMA Internal Medicine</i> , 2016, 176, 603.	2.6	31
113	Factors associated with poor outcomes among adults hospitalized for influenza in France: A three-year prospective multicenter study. <i>Journal of Clinical Virology</i> , 2016, 79, 68-73.	1.6	65
114	Reply to "A strong message is needed to address the issue of HCC recurrence after DAA therapy". <i>Journal of Hepatology</i> , 2016, 65, 1269-1270.	1.8	6
115	Intensification with pegylated interferon during treatment with tenofovir in HIV/Hepatitis B virus coinfected patients. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1017-1026.	1.0	10
116	Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic?. <i>Pediatric Nephrology</i> , 2016, 31, 2299-2308.	0.9	29
117	Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 633-639.	0.8	9
118	Vaccination Against Hepatitis B Virus (HBV) in HIV-1 Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 1735-1742.	1.9	27
119	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	3.0	44
120	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	1.1	19
121	No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. <i>PLoS ONE</i> , 2016, 11, e0168640.	1.1	8
122	Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitor-based therapy. <i>Liver International</i> , 2015, 35, 1833-1844.	1.9	5
123	Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study. <i>Vaccine</i> , 2015, 33, 7015-7021.	1.7	3
124	Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. <i>Liver International</i> , 2015, 35, 1950-1958.	1.9	16
125	IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0121395.	1.1	8
126	Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections. <i>PLoS ONE</i> , 2015, 10, e0130378.	1.1	58

#	ARTICLE	IF	CITATIONS
127	Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv162.	0.4	61
128	Towards an HBV cure: state-of-the-art and unresolved questionsâ€”report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	6.1	234
129	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimenâ€”The ANRS CO20-CUIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 443-450.	0.7	5
130	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and Bâ€œcell nonâ€œHodgkin lymphomas, ANRS HCâ€œ13 lymphoâ€œC study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	2.0	84
131	Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1283-1291.	4.6	45
132	Causal analysis of H1N1pdm09 influenza infection risk in a household cohort. <i>Journal of Epidemiology and Community Health</i> , 2015, 69, 272-277.	2.0	11
133	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. <i>Journal of Hepatology</i> , 2015, 62, 807-815.	1.8	54
134	Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1096-1107.	0.6	43
135	Risk factors of pandemic influenza A / H 1 N 1 in a prospective household cohort in the general population: results from the C o P an F luâ€œF rance cohort. <i>Influenza and Other Respiratory Viruses</i> , 2015, 9, 43-50.	1.5	13
136	Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1135-7.	1.4	3
137	Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with <sc>HCV</sc>â€œgenotype 4 in <sc>E</sc>gypt. <i>Journal of Viral Hepatitis</i> , 2015, 22, 245-253.	1.0	35
138	Auto-Immune Origin of B Cells from HCV-Associated Lymphoma. <i>Blood</i> , 2015, 126, 1464-1464.	0.6	2
139	Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUIC Study. <i>PLoS ONE</i> , 2015, 10, e0145105.	1.1	4
140	Comparing Patientsâ€™ Opinions on the Hospital Discharge Process Collected With a Self-Reported Questionnaire Completed Via the Internet or Through a Telephone Survey: An Ancillary Study of the SENTIPAT Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2015, 17, e158.	2.1	8
141	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015, 21, 5647.	1.4	13
142	Multiplex PCR performed of bronchoalveolar lavage fluid increases pathogen identification rate in critically ill patients with pneumonia: a pilot study. <i>Annals of Intensive Care</i> , 2014, 4, 35.	2.2	32
143	A Sero-epidemiological Study of Arboviral Fevers in Djibouti, Horn of Africa. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3299.	1.3	54
144	Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study. <i>PLoS Computational Biology</i> , 2014, 10, e1003568.	1.5	60

#	ARTICLE	IF	CITATIONS
145	Radiologic course of primary sclerosing cholangitis: Assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. <i>Hepatology</i> , 2014, 59, 242-250.	3.6	102
146	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 712-720.	1.9	59
147	Clinical validation of IFN β /IL-10 and IFN β /IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 104-113.	1.4	17
148	Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1324-1329.	2.4	86
149	Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response. <i>Journal of Infection</i> , 2014, 68, 462-466.	1.7	1
150	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	0.6	232
151	Determinants of individuals' risks to 2009 pandemic influenza virus infection at household level amongst Djibouti city residents - A CoPanFlu cross-sectional study. <i>Virology Journal</i> , 2014, 11, 13.	1.4	7
152	Statin and aspirin for prevention of hepatocellular carcinoma: What are the levels of evidence?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 9-11.	0.7	20
153	Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey. <i>Autoimmunity Reviews</i> , 2014, 13, 630-634.	2.5	23
154	Public Health and Economic Impact of Vaccinating Children with a Quadrivalent live Attenuated Influenza Vaccine in France Using a Dynamic Transmission Model. <i>Value in Health</i> , 2014, 17, A674.	0.1	2
155	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014, 63, 1416-1423.	6.1	122
156	Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5332-5341.	1.4	8
157	Detection of independent associations in a large epidemiologic dataset: a comparison of random forests, boosted regression trees, conventional and penalized logistic regression for identifying independent factors associated with H1N1pdm influenza infections. <i>BMC Medical Research Methodology</i> , 2014, 14, 99.	1.4	34
158	Influenza C virus high seroprevalence rates observed in 3 different population groups. <i>Journal of Infection</i> , 2014, 69, 182-189.	1.7	27
159	Baseline Values and Changes in Liver Stiffness Measured by Transient Elastography Are Associated With Severity of Fibrosis and Outcomes of Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2014, 146, 970-979.e6.	0.6	232
160	Reply to: From the CUPIC study: Great times are not coming (?). <i>Journal of Hepatology</i> , 2014, 60, 235-236.	1.8	0
161	Reply to: "From the CUPIC study: Great times are not coming (?)" <i>Journal of Hepatology</i> , 2014, 60, 900-901.	1.8	0
162	Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. <i>Journal of Hepatology</i> , 2014, 61, 761-769.	1.8	14

#	ARTICLE	IF	CITATIONS
163	Characterization of pandemic influenza immune memory signature after vaccination or infection. <i>Journal of Clinical Investigation</i> , 2014, 124, 3129-3136.	3.9	26
164	Current State of and Needs for Hepatitis B Screening: Results of a Large Screening Study in a Low-Prevalent, Metropolitan Region. <i>PLoS ONE</i> , 2014, 9, e92266.	1.1	15
165	Representations of influenza and influenza-like illness in the community - a qualitative study. <i>BMC Family Practice</i> , 2013, 14, 15.	2.9	14
166	Current management and recommendations on hepatitis B therapy in HIV-coinfected patients. <i>Hepatology International</i> , 2013, 7, 437-442.	1.9	3
167	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) â€” NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	1.8	407
168	Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. <i>Journal of Hepatology</i> , 2013, 58, 473-478.	1.8	58
169	Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infectionsâ€”The Fluco French cohort. <i>Journal of Clinical Virology</i> , 2013, 58, 114-119.	1.6	6
170	The influenza A (H1N1) pandemic in Reunion Island: knowledge, perceived risk and precautionary behaviour. <i>BMC Infectious Diseases</i> , 2013, 13, 34.	1.3	20
171	Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2013, 145, 166-175.e8.	0.6	311
172	Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008â€”2009 winter. <i>Clinical Microbiology and Infection</i> , 2013, 19, 196-203.	2.8	10
173	Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination. <i>Journal of Immunology</i> , 2013, 191, 623-631.	0.4	21
174	Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 374-380.	0.5	59
175	Field seasonal influenza vaccine effectiveness. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2453-2459.	1.4	9
176	Incidence, Presentation, and Prognosis of Small Bowel Adenocarcinoma in Patients with Small Bowel Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	0.9	53
177	Factors Associated with Post-Seasonal Serological Titer and Risk Factors for Infection with the Pandemic A/H1N1 Virus in the French General Population. <i>PLoS ONE</i> , 2013, 8, e60127.	1.1	21
178	2009 A(H1N1) Seroconversion Rates and Risk Factors among the General Population in Vientiane Capital, Laos. <i>PLoS ONE</i> , 2013, 8, e61909.	1.1	12
179	Trends in influenza vaccination behaviours â€” results from the CoPanFlu cohort, France, 2006 to 2011. <i>Eurosurveillance</i> , 2013, 18, 20628.	3.9	25
180	Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. <i>Blood</i> , 2013, 122, 3005-3005.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Risk of Melanoma in Patients Who Receive Thiopurines for Inflammatory Bowel Disease Is Not Increased. <i>American Journal of Gastroenterology</i> , 2012, 107, 1443-1444.	0.2	31
182	Assessment and determinants of aesthetic discomfort in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 45-49.	0.5	34
183	Effect of Oseltamivir, Zanamivir or Oseltamivir+ Zanamivir Combination Treatments on Transmission of Influenza in Households. <i>Antiviral Therapy</i> , 2012, 17, 1085-1090.	0.6	30
184	Long-term Outcomes of Pandemic 2009 Influenza A(H1N1)-Associated Severe ARDS. <i>Chest</i> , 2012, 142, 583-592.	0.4	199
185	Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Blood</i> , 2012, 119, 5996-6004.	0.6	175
186	A Short-Term, Multicomponent Infection Control Program in Nursing Homes: A Cluster Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 569.e9-569.e17.	1.2	23
187	Integrative study of pandemic A/H1N1 influenza infections: design and methods of the CoPanFlu-France cohort. <i>BMC Public Health</i> , 2012, 12, 417.	1.2	15
188	Simultaneous investigation of influenza and enteric viruses in the stools of adult patients consulting in general practice for acute diarrhea. <i>Virology Journal</i> , 2012, 9, 116.	1.4	24
189	Estimating influenza latency and infectious period durations using viral excretion data. <i>Epidemics</i> , 2012, 4, 132-138.	1.5	58
190	Intense Co-Circulation of Non-Influenza Respiratory Viruses during the First Wave of Pandemic Influenza pH1N1/2009: A Cohort Study in Reunion Island. <i>PLoS ONE</i> , 2012, 7, e44755.	1.1	34
191	Hepatitis E Virus Infection in Sheltered Homeless Persons, France. <i>Emerging Infectious Diseases</i> , 2012, 18, 1031-1032.	2.0	7
192	Broad respiratory virus detection in infants hospitalized for bronchiolitis by use of a multiplex RT-PCR DNA microarray system. <i>Journal of Medical Virology</i> , 2012, 84, 979-985.	2.5	64
193	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. <i>Hepatology</i> , 2012, 56, 198-208.	3.6	277
194	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2063-2071.	0.9	96
195	Severe transaminitis after interferon+ribavirin therapy in HIV/HCV+coinfecting patients: influence of a sustained HCV response. <i>Journal of Viral Hepatitis</i> , 2012, 19, 431-435.	1.0	4
196	Mortality Burden of the 2009 A/H1N1 Influenza Pandemic in France: Comparison to Seasonal Influenza and the A/H3N2 Pandemic. <i>PLoS ONE</i> , 2012, 7, e45051.	1.1	72
197	Contribution of Genome-Wide Association Studies to Scientific Research: A Bibliometric Survey of the Citation Impacts of GWAS and Candidate Gene Studies Published during the Same Period and in the Same Journals. <i>PLoS ONE</i> , 2012, 7, e51408.	1.1	16
198	Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. <i>Gut</i> , 2011, 60, 198-203.	6.1	160

#	ARTICLE	IF	CITATIONS
199	Integrating the applicability rate into the performance evaluation of noninvasive staging of liver fibrosis: A step towards a change from the "accuracy" to the "clinical" paradigm. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 691-692.	0.7	1
200	Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 141, 1621-1628.e5.	0.6	431
201	Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 756-761.	1.8	89
202	Age distribution of cases and deaths during the 1889 influenza pandemic. <i>Vaccine</i> , 2011, 29, B6-B10.	1.7	15
203	Field Effectiveness of Pandemic and 2009-2010 Seasonal Vaccines against 2009-2010 A(H1N1) Influenza: Estimations from Surveillance Data in France. <i>PLoS ONE</i> , 2011, 6, e19621.	1.1	25
204	Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 188-195.	1.9	55
205	Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. <i>Clinical Microbiology and Infection</i> , 2011, 17, 732-737.	2.8	19
206	Impact of bucco-dental healthcare on the prevention of pneumonia in geriatrics: a cluster-randomised trial. <i>Journal of Hospital Infection</i> , 2011, 77, 78-80.	1.4	14
207	Guidelines for infection control in nursing homes: a Delphi consensus web-based survey. <i>Journal of Hospital Infection</i> , 2011, 79, 75-89.	1.4	21
208	Burden of infections among 44,869 elderly in nursing homes: a cross-sectional cluster nationwide survey. <i>Journal of Hospital Infection</i> , 2011, 79, 254-259.	1.4	36
209	Randomised active programs on healthcareworkers' flu vaccination in geriatric health care settings in France: The VESTA study. <i>Journal of Nutrition, Health and Aging</i> , 2011, 15, 126-132.	1.5	19
210	Nationwide surveillance of 18 respiratory viruses in patients with influenza-like illnesses: A pilot feasibility study in the French Sentinel Network. <i>Journal of Medical Virology</i> , 2011, 83, 1451-1457.	2.5	21
211	Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1432.	3.8	157
212	Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. <i>New England Journal of Medicine</i> , 2011, 365, 2067-2077.	13.9	683
213	Explaining rapid reinfections in multiple-wave influenza outbreaks: Tristan da Cunha 1971 epidemic as a case study. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2011, 278, 3635-3643.	1.2	43
214	Population Modeling of Influenza A/H1N1 Virus Kinetics and Symptom Dynamics. <i>Journal of Virology</i> , 2011, 85, 2764-2770.	1.5	90
215	Pandemic Influenza Due to pH1N1/2009 Virus: Estimation of Infection Burden in Reunion Island through a Prospective Serosurvey, Austral Winter 2009. <i>PLoS ONE</i> , 2011, 6, e25738.	1.1	22
216	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. <i>PLoS ONE</i> , 2011, 6, e26783.	1.1	41

#	ARTICLE	IF	CITATIONS
217	Risk perception and priority setting for intervention among hepatitis C virus and environmental risks: a cross-sectional survey in the Cairo community. <i>BMC Public Health</i> , 2010, 10, 773.	1.2	5
218	Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. <i>BMC Infectious Diseases</i> , 2010, 10, 162.	1.3	97
219	Planning for the next influenza H1N1 season: a modelling study. <i>BMC Infectious Diseases</i> , 2010, 10, 301.	1.3	13
220	Surgical Mask to Prevent Influenza Transmission in Households: A Cluster Randomized Trial. <i>PLoS ONE</i> , 2010, 5, e13998.	1.1	84
221	Response to anti-HCV therapy in HIV/HCV-coinfected patients: does the lipid profile really have an effect?. <i>Antiviral Therapy</i> , 2010, 15, 797-800.	0.6	3
222	Transmissibility and geographic spread of the 1889 influenza pandemic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8778-8781.	3.3	105
223	Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina Faso. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 454-458.	0.6	66
224	WTWâ€”an algorithm for identifying â€œwho transmits to whomâ€”in outbreaks of interhuman transmitted infectious agents. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2010, 17, 348-353.	2.2	3
225	Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. <i>Journal of Hepatology</i> , 2010, 53, 238-244.	1.8	38
226	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. <i>Journal of Hepatology</i> , 2010, 53, 1006-1012.	1.8	46
227	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. <i>Gut</i> , 2010, 59, 1363-1368.	6.1	155
228	Assessment of healthcare worker influenza vaccination program in French geriatric wards: a cluster-randomized controlled trial. <i>Aging Clinical and Experimental Research</i> , 2010, 22, 450-455.	1.4	13
229	Does nonadherence to local recommendations for empirical antibiotic therapy on admission to the intensive care unit have an impact on in-hospital mortality?. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 491.	0.9	7
230	Diagnosis Scoring for Clinical Identification of Children With Heterozygous Familial Hypercholesterolemia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, 456-463.	0.9	19
231	Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) monoâ€”infected compared with HIVâ€”HCV coâ€”infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 61-70.	1.9	30
232	Mortality burden of the 1918â€”1919 influenza pandemic in Europe. <i>Influenza and Other Respiratory Viruses</i> , 2009, 3, 99-106.	1.5	113
233	Effect of Influenza Vaccination of Nursing Home Staff on Mortality of Residents: A Clusterâ€”Randomized Trial. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 1580-1586.	1.3	222
234	Persistently normal alanine aminotransferase levels in HIV/HCVâ€”coinfected patients: the role of steatosis. <i>HIV Medicine</i> , 2009, 10, 417-421.	1.0	5

#	ARTICLE	IF	CITATIONS
235	“If you have the flu symptoms, your asymptomatic spouse may better answer the willingness-to-pay question” Journal of Health Economics, 2009, 28, 873-884.	1.3	10
236	Liver biopsy: The best, not the gold standard. Journal of Hepatology, 2009, 50, 1-3.	1.8	289
237	Liver fibrosis: Screening is not staging. Journal of Hepatology, 2009, 50, 1268-1269.	1.8	4
238	81 Thiopurine Therapy Is Associated with a Three-Fold Decrease in the Incidence of Advanced Colorectal Neoplasia in IBD Patients with Longstanding Extensive Colitis: Results from the CESAME Cohort. Gastroenterology, 2009, 136, A-54.	0.6	16
239	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, The, 2009, 374, 1617-1625.	6.3	996
240	Gamma Glutamyl Transferase Elevation in HIV/Hepatitis C Virus-Coinfected Patients During Interferon-Ribavirin Combination Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 429-430.	0.9	10
241	Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV“hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antiviral Therapy, 2009, 14, 839-845.	0.6	25
242	Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: Clinical and economic impact. PLOS Currents, 2009, 1, RRN1121.	1.4	5
243	Effect of Antiviral Treatment on Serum Markers of Liver Fibrosis in HIV“Hepatitis C virus-Coinfected Patients: The Fibrovic 2 Study “ ANRS HC02. Antiviral Therapy, 2009, 14, 211-219.	0.6	21
244	Quality of leucoreduced red blood cell concentrates: 5“years of follow-up in France. Vox Sanguinis, 2008, 94, 41-47.	0.7	18
245	Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. Journal of Viral Hepatitis, 2008, 15, 255-260.	1.0	21
246	Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study “ ANRS HC02. Journal of Hepatology, 2008, 48, 765-773.	1.8	87
247	Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV“HCV co-infected patients on HCV therapy. Journal of Hepatology, 2008, 49, 892-898.	1.8	13
248	“valuation de l'incidence de la cirrhose biliaire primitive en 2007 en France. Revue Francophone Des Laboratoires, 2008, 2008, 25-28.	0.0	0
249	Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. American Journal of Epidemiology, 2008, 167, 775-785.	1.6	927
250	Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patients. Aids, 2008, 22, 1234-1236.	1.0	6
251	How to Measure the Diagnostic Accuracy of Noninvasive Liver Fibrosis Indices: The Area Under the ROC Curve Revisited. Clinical Chemistry, 2008, 54, 1372-1378.	1.5	119
252	Progression of Fibrosis in HIV and Hepatitis C Virus-Coinfected Patients Treated with Interferon plus Ribavirin-Based Therapy: Analysis of Risk Factors. Clinical Infectious Diseases, 2008, 46, 768-774.	2.9	55

#	ARTICLE	IF	CITATIONS
253	Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. <i>Aids</i> , 2008, 22, 1385-1387.	1.0	6
254	Serum alpha-fetoprotein predicts virologic response to Hepatitis C treatment in HIV coinfected patients. <i>Aids</i> , 2008, 22, 1513-1515.	1.0	3
255	Rapid and early virological response to chronic hepatitis C treatment with IFN α 2b or PEG-IFN α 2b plus ribavirin in HIV/HCV co-infected patients. <i>Gut</i> , 2007, 56, 1111-1116.	6.1	46
256	High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?. <i>Aids</i> , 2007, 21, 1645-1648.	1.0	16
257	Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005) <i>Tj ETQq1 1 0.784314 rgBT /Overload</i>	1.0	53
258	Early Virologic Failure in HIV-Coinfected Hepatitis C Patients Treated With the Peginterferon-Ribavirin Combination. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 123-125.	0.9	85
259	Viral pneumonia and respiratory sepsis: Association, causation, or it depends?*. <i>Critical Care Medicine</i> , 2007, 35, 639-640.	0.4	2
260	General practitioners' management of influenza with or without neuraminidase inhibitors. <i>European Journal of General Practice</i> , 2007, 13, 157-159.	0.9	1
261	Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2007, 14, 639-644.	1.0	24
262	The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model. <i>Value in Health</i> , 2007, 10, 98-116.	0.1	60
263	Online detection and quantification of epidemics. <i>BMC Medical Informatics and Decision Making</i> , 2007, 7, 29.	1.5	50
264	Predicting Pneumonia and Influenza Mortality from Morbidity Data. <i>PLoS ONE</i> , 2007, 2, e464.	1.1	26
265	Risk Factors for Acute Liver Enzyme Abnormalities in HIV-Hepatitis B Virus-Coinfected Patients on Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2007, 12, 1115-1126.	0.6	8
266	Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. <i>Journal of Hepatology</i> , 2006, 44, 455-461.	1.8	79
267	Repeated influenza vaccination of healthy children and adults: borrow now, pay later?. <i>Epidemiology and Infection</i> , 2006, 134, 63-70.	1.0	27
268	Detailed analysis of the genetic evolution of influenza virus during the course of an epidemic. <i>Epidemiology and Infection</i> , 2006, 134, 514-520.	1.0	25
269	Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. <i>Aids</i> , 2006, 20, 419-427.	1.0	107
270	A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. <i>Journal of Viral Hepatitis</i> , 2006, 13, 775-782.	1.0	85

#	ARTICLE	IF	CITATIONS
271	A virologic survey of patients admitted to a critical care unit for acute cardiorespiratory failure. <i>Intensive Care Medicine</i> , 2006, 32, 156-159.	3.9	31
272	A 'small-world-like' model for comparing interventions aimed at preventing and controlling influenza pandemics. <i>BMC Medicine</i> , 2006, 4, 26.	2.3	88
273	Hepatic steatosis in HIV/HCV coinfecting patients: analysis of risk factors. <i>Aids</i> , 2006, 20, 525-531.	1.0	77
274	Heterosubtypic Immunity to Influenza: Right Hypothesis, Wrong Comparison. <i>Journal of Infectious Diseases</i> , 2006, 193, 1613-1613.	1.9	3
275	Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin. <i>Journal of Clinical Microbiology</i> , 2006, 44, 417-422.	1.8	10
276	Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 47-52.	0.9	82
277	Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. <i>Epidemiology and Infection</i> , 2005, 133, 305-314.	1.0	9
278	Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment. <i>Clinical Infectious Diseases</i> , 2005, 41, 1806-1809.	2.9	41
279	The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. <i>Gastroenterology</i> , 2005, 128, 297-303.	0.6	367
280	Influenza Epidemics in the United States, France, and Australia, 1972-1997. <i>Emerging Infectious Diseases</i> , 2004, 10, 32-39.	2.0	121
281	Detection of Lung Cancer on Radiographs: Receiver Operating Characteristic Analyses of Radiologists', Pulmonologists', and Anesthesiologists' Performance. <i>Radiology</i> , 2004, 233, 799-805.	3.6	40
282	Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2839.	3.8	742
283	A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. <i>Statistics in Medicine</i> , 2004, 23, 3469-3487.	0.8	322
284	Chronic hepatitis C virus infection: Does it really impact health-related quality of life? A study in rural Egypt. <i>Hepatology</i> , 2004, 40, 1434-1441.	3.6	38
285	Exploring cross-protection between influenza strains by an epidemiological model. <i>Virus Research</i> , 2004, 103, 101-105.	1.1	24
286	Risk factors of influenza transmission in households. <i>International Congress Series</i> , 2004, 1263, 291-294.	0.2	97
287	A systematic analysis of all ICD10-coded death certificates in France, 2000, with a mention of influenza as cause of death. <i>International Congress Series</i> , 2004, 1263, 299-303.	0.2	2
288	Factors associated with intensity of symptoms in patients seeking medical advice for flu. <i>International Congress Series</i> , 2004, 1263, 308-311.	0.2	1

#	ARTICLE	IF	CITATIONS
289	Risk factors of influenza transmission in households. <i>British Journal of General Practice</i> , 2004, 54, 684-9.	0.7	241
290	Antibiotic Treatment for Influenza does not Affect Resolution of Illness, Secondary Visits or Lost Workdays. <i>European Journal of Epidemiology</i> , 2003, 19, 703-705.	2.5	14
291	Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. <i>Vaccine</i> , 2003, 21, 3614-3622.	1.7	28
292	Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working Adults. <i>Pharmacoeconomics</i> , 2003, 21, 215-224.	1.7	10
293	Prediction of the Spread of Influenza Epidemics by the Method of Analogues. <i>American Journal of Epidemiology</i> , 2003, 158, 996-1006.	1.6	107
294	Economic evaluations of neuraminidase inhibitors to control influenza. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2003, 3, 147-158.	0.7	5
295	Influenza Burden of Illness. <i>Archives of Internal Medicine</i> , 2002, 162, 1842.	4.3	117
296	Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients. <i>Gastroenterology</i> , 2002, 122, 652-658.	0.6	168
297	Quality control of leucoreduced cellular blood components in France. <i>Vox Sanguinis</i> , 2002, 82, 67-71.	0.7	11
298	Quantifying the burden of influenza: a prospective household contact study in France. <i>International Congress Series</i> , 2001, 1219, 61-66.	0.2	1
299	How much are patients willing to pay for an earlier alleviation of influenza?. <i>International Congress Series</i> , 2001, 1219, 67-71.	0.2	1
300	Rapid flu test and neuraminidase inhibitors in healthy adults: a cost-benefit analysis. <i>International Congress Series</i> , 2001, 1219, 73-79.	0.2	0
301	Severe Accidental Hypothermia Treated in an ICU. <i>Chest</i> , 2001, 120, 1998-2003.	0.4	111
302	The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. <i>Hepatology</i> , 2000, 32, 1196-1199.	3.6	265
303	Comparison of a New Method for the Direct and Simultaneous Assessment of LDL- and HDL-Cholesterol with Ultracentrifugation and Established Methods. <i>Clinical Chemistry</i> , 2000, 46, 493-505.	1.5	31
304	A Scale of Methodological Quality for Clinical Studies of Radiologic Examinations. <i>Radiology</i> , 2000, 217, 69-74.	3.6	36
305	Evaluation of Clinical Case Definitions of Influenza: Detailed Investigation of Patients During the 1995-1996 Epidemic in France. <i>Clinical Infectious Diseases</i> , 1999, 28, 283-290.	2.9	143
306	Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. <i>Gut</i> , 1999, 45, 218-222.	6.1	84

#	ARTICLE	IF	CITATIONS
307	Effects of current and former cigarette smoking on the clinical course of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1403-1411.	1.9	179
308	Monitoring epidemiologic surveillance data using hidden Markov models. , 1999, 18, 3463-3478.		126
309	Risk of hepatitis C virus transmission to surgeons and nurses from infected patients: model-based estimates in France. <i>Journal of Hepatology</i> , 1999, 30, 765-769.	1.8	32
310	Air Pollution and Respiratory Drug Sales in the City of Le Havre, France, 1993-1996. <i>Environmental Research</i> , 1999, 81, 224-230.	3.7	19
311	Factors of Weight Loss in Patients With HIV and Chronic Diarrhea. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 34-39.	0.3	22
312	Effect of indinavir on HIV-related wasting. <i>Aids</i> , 1998, 12, 1777-1784.	1.0	51
313	A new out-patient care facility for HIV-infected destitute populations in Paris, France. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 1997, 9, 451-459.	0.6	13
314	Influenza and influenza-like illness in general practice: drawing lessons for surveillance from a pilot study in Paris, France. <i>British Journal of General Practice</i> , 1997, 47, 217-20.	0.7	13
315	Influenza mortality among the elderly in France, 1980-90: how many deaths may have been avoided through vaccination?. <i>Journal of Epidemiology and Community Health</i> , 1995, 49, 419-425.	2.0	57
316	Consequences of Misdiagnosis of Intrauterine Growth Retardation for Preterm Elective Cesarean Section. <i>Fetal Diagnosis and Therapy</i> , 1993, 8, 325-330.	0.6	10
317	Epidemiologic Mapping using the "Kriging" Method: Application to an Influenza-like Epidemic in France. <i>American Journal of Epidemiology</i> , 1992, 135, 1293-1300.	1.6	152
318	Effect of Maternal and Fetal Characteristics on Diagnosis of Intrauterine Growth Retardation. <i>Fetal Diagnosis and Therapy</i> , 1990, 5, 114-123.	0.6	1
319	Seroprevalence of SARS-CoV-2 Among Adults in Three Regions of France Following the Lockdown and Associated Risk Factors: A Multicohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	15
320	SARS CoV-2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine Based PrEP in 2020 - A Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero Cohorts. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	5